ReviewDiabetes, obesity & metabolism2025

What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.

Juan Pablo FriasPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.